Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | CHAT | P28329 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057931 | 1.00 | NFE2L2 (0.55) | NFE2L2CYP1A2CYP2C9FBP1PTGES2 | |
| SCHEMBL4658396 | 0.85 | CYP1A2 (0.59) | NFE2L2CYP1A2CYP2C9FBP1PTGES2 | |
| SCHEMBL4658400 | 0.85 | CYP1A2 (0.59) | NFE2L2CYP1A2CYP2C9FBP1PTGES2 | |
| SCHEMBL11534918 | 0.83 | NFE2L2 (0.54) | NFE2L2CYP1A2CYP2C9FBP1PTGES2 | |
| SCHEMBL11534915 | 0.83 | NFE2L2 (0.54) | NFE2L2CYP1A2CYP2C9FBP1PTGES2 | |
| SCHEMBL14603114 | 0.79 | ALDH1A1 (0.57) | NFE2L2MAOBMAOARELAMAPT | |
| SCHEMBL14861070 | 0.79 | ALDH1A1 (0.57) | NFE2L2MAOBMAOARELAMAPT | |
| SCHEMBL29178131 | 0.79 | NFE2L2 (0.61) | NFE2L2CYP1A2CYP2C9MAOB | |
| SCHEMBL29178129 | 0.79 | NFE2L2 (0.61) | NFE2L2CYP1A2CYP2C9MAOB | |
| SCHEMBL699364 | 0.79 | CHAT (0.67) | NFE2L2CYP1A2CYP2C9FBP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730913-B2 | High affinity beta lactamase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-9371307-B2 | Serine protease inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150080451-A1 | SERINE PROTEASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140256778-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013056079-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013039985-A2 | SERINE PROTEASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2009120783-A1 | HIGH AFFINITY INHIBITORS OF HEPATITIS C VIRUS NS3/4A PROTEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-0650480-B1 | 1-ARYLSULPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMA CORP (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5684151-A | PROGESTIN AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0650480-A1 | 1-ARYLSULPHONYL, ARYLCARBONYL AND 1-ARYLPHOSPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994001412-A1 | 1-ARYLSULPHONYL, ARYLCARBONYL AND 1-ARYLPHOSPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256778-A1 | HIGH AFFINITY BETA LACTAMASE INHIBITORS | ALPI, GUSB, LCT | NFE2L2 3722/4885CYP1A2 858/4885CYP2C9 779/4885 |
| US-20150080451-A1 | SERINE PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | NFE2L2 4765/4885CYP1A2 4318/4885CYP2C9 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.